Amneal Pharmaceuticals Inc
NYSE:AMRX
Intrinsic Value
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. [ Read More ]
The intrinsic value of one
AMRX
stock under the Base Case scenario is
13.38
USD.
Compared to the current market price of 5.42 USD,
Amneal Pharmaceuticals Inc
is
Undervalued by 59%.
Amneal Pharmaceuticals Inc's market capitalization is 1.7B USD.
AMRX stock price is 5.42 USD.
AMRX stock price (5.42 USD) is 59% less than its Intrinsic Value (13.38 USD).
AMRX has upside potential of 38% compared to the average analyst price target.
Open Wall St Estimates
AMRX's long-term assets (3B USD) exceed its long-term liabilties (3B USD).
AMRX's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 10%.
AMRX has positive Operating Income for the last twelve months.
AMRX's Revenue has grown by 8% over the past 12 months.
AMRX's Revenue is forecast to grow at a rate of 6% per year over the next 3 years.
AMRX's Revenue has been growing by 6% per year for the last 3 years.
AMRX's ROIC (Return on Invested Capital) has increased in the last 3 years from 4% to 10%.
AMRX has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
AMRX has positive Free Cash Flow for the last twelve months.
AMRX's short-term assets (1B USD) exceed its short-term liabilties (847m USD).
AMRX has negative Net Income for the last twelve months.
AMRX's ROE (Return on Equity) has significantly decreased in the last 3 years from -5% to -53%, and is approaching profitability.
AMRX has positive Gross Profit for the last twelve months.
AMRX's ROE (Return on Equity) for the past 12 months is negative and is equal to -53%.
AMRX's Altman Z-Score is very low and is equal to 1.29.
AMRX has negative three-year average ROE (Return on Equity): -13%. The company is not efficient at transforming stockholders' equity into net income.
AMRX has positive Net Debt. This means that the company has more debt (3B USD) than cash and short-term investments (92m USD).
AMRX's D/E (Debt to Equity) is very high and is equal to 134.73.
AMRX generates enough operating income (275m USD) to cover interest payments on its debt (193m USD).
Valuation Backtest
Amneal Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
AMRX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Amneal Pharmaceuticals Inc
Balance Sheet Decomposition
Amneal Pharmaceuticals Inc
| Current Assets | 1.4B |
| Cash & Short-Term Investments | 91.5m |
| Receivables | 645.7m |
| Other Current Assets | 640.7m |
| Non-Current Assets | 2.1B |
| PP&E | 550.1m |
| Intangibles | 1.5B |
| Other Non-Current Assets | 55.5m |
| Current Liabilities | 846.6m |
| Accounts Payable | 143.6m |
| Accrued Liabilities | 403.1m |
| Short-Term Debt | 179m |
| Other Current Liabilities | 120.9m |
| Non-Current Liabilities | 2.6B |
| Long-Term Debt | 2.5B |
| Other Non-Current Liabilities | 120.2m |
Earnings Waterfall
Amneal Pharmaceuticals Inc
|
Revenue
|
2.4B
USD
|
|
Cost of Revenue
|
-1.5B
USD
|
|
Gross Profit
|
856.7m
USD
|
|
Operating Expenses
|
-581.8m
USD
|
|
Operating Income
|
274.8m
USD
|
|
Other Expenses
|
-358.8m
USD
|
|
Net Income
|
-84m
USD
|
Free Cash Flow Analysis
Amneal Pharmaceuticals Inc
What is Free Cash Flow?
AMRX Profitability Score
Profitability Due Diligence
Amneal Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Amneal Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
AMRX Solvency Score
Solvency Due Diligence
Amneal Pharmaceuticals Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Score
Amneal Pharmaceuticals Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMRX Price Targets Summary
Amneal Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
AMRX
is 7.46 USD
with a low forecast of 6.31 USD and a high forecast of 8.4 USD.
Ownership
AMRX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AMRX Price
Amneal Pharmaceuticals Inc
| Average Annual Return | -29.4% |
| Standard Deviation of Annual Returns | 35.05% |
| Max Drawdown | -91% |
| Market Capitalization | 1.7B USD |
| Shares Outstanding | 308 553 984 |
| Percentage of Shares Shorted | 0.93% |
Company Profile
Amneal Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 7,000 full-time employees. The company went IPO on 2009-03-16. The firm specializes in developing, manufacturing, marketing and distributing generic and branded specialty pharmaceutical products. The company operates through three segments: Generics, Specialty, and AvKARE. Its Generics segment includes approximately 250 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company operates principally in the United States, India and Ireland.
Contact
IPO
Employees
Officers
The intrinsic value of one
AMRX
stock under the Base Case scenario is
13.38
USD.
Compared to the current market price of 5.42 USD,
Amneal Pharmaceuticals Inc
is
Undervalued by 59%.
You don't have any saved screeners yet
